Jamp India Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 17-11-2024
- Paid Up Capital ₹ 0.10 M
as on 17-11-2024
- Company Age 7 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue 51.03%
(FY 2023)
- Profit 930.07%
(FY 2023)
- Ebitda 148.17%
(FY 2023)
- Net Worth 80.62%
(FY 2023)
- Total Assets 41.02%
(FY 2023)
About Jamp India Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Raveesh Grover, Alpeshkumar Thakkar, David Dimeo, and One other member serve as directors at the Company.
- CIN/LLPIN
U73100GJ2017FTC099869
- Company No.
099869
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
20 Nov 2017
- Date of AGM
27 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Jamp India Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raveesh Grover  | Director | 20-Nov-2017 | Current |
| Alpeshkumar Thakkar | Director | 30-Mar-2021 | Current |
| David Dimeo | Director | 24-Oct-2024 | Current |
| Marcandre Huot | Director | 24-Oct-2024 | Current |
Financial Performance of Jamp India Pharmaceuticals.
Jamp India Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 51.03% increase. The company also saw a substantial improvement in profitability, with a 930.07% increase in profit. The company's net worth Soared by an impressive increase of 80.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jamp India Pharmaceuticals?
In 2023, Jamp India Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Nexcellife Research Labs Private LimitedActive 2 months 2 daysAlpeshkumar Thakkar and Marcandre Huot are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Jamp India Pharmaceuticals?
Jamp India Pharmaceuticals has a workforce of 323 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jamp India Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jamp India Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
